Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 7/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.45 |
| ▸ | ESR1 | P03372 | 8/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5035638 | 0.86 | PGR (0.57) | PGRESR2ESR1NR3C1AR | |
| SCHEMBL6928534 | 0.85 | PGR (0.55) | PGRNR3C1ARMAOA | |
| SCHEMBL2394299 | 0.84 | PGR (0.55) | PGRNR3C1AR | |
| Hydrochloric Acid SCHEMBL6723833 | 0.84 | PGR (0.54) | PGRNR3C1ARMAOA | |
| SCHEMBL5034787 | 0.82 | PGR (0.52) | PGRNR3C1 | |
| SCHEMBL2391670 | 0.81 | PGR (0.53) | PGRESR2ESR1NR3C1AR | |
| SCHEMBL2393047 | 0.81 | PGR (0.73) | PGRESR2ESR1NR3C1AR | |
| SCHEMBL5035576 | 0.80 | PGR (0.50) | PGRNR3C1AR | |
| SCHEMBL2395756 | 0.80 | PGR (0.54) | PGRESR2ESR1NR3C1AR | |
| SCHEMBL12886106 | 0.79 | PGR (0.74) | PGRESR2ESR1NR3C1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1944290-B1 | NOVEL 1-2-DIHYDROQUINOLINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-8017775-B2 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017775-B2 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-8017775-B2 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | Santen Pharmaceutical Co., (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | Santen Pharmaceutical Co., (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | Santen Pharmaceutical Co., (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1944290-A1 | NOVEL 1-2-DIHYDROQUINOLINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944290-A1 | NOVEL 1-2-DIHYDROQUINOLINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | NR3C1, NR3C2, NR5A1 | PGR 201/4885ESR2 186/4885ESR1 586/4885 |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | NR3C1, NR3C2, NR5A1 | PGR 257/4885ESR2 216/4885ESR1 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.